As the incidence of these complications is low, we can still prescribe as is clinically indicated
Other approaches win on availability or novelty
These symptoms could mask disease flares, complicate assessment of treatment response to IBD-specific therapies, or reduce quality of life in patients already burdened by gastrointestinal symptoms
Pubchem Draft Guidance on Semaglutide, August 2021 Vinayak Bhosale Corresponding author Bioanalytical Department, Bion Clinicals Pvt Ltd, Pune, India Deepak Bagde Co-author Bion Clinicals Pvt Ltd, Pune, India Vishwas Pukale Co-author Bion Clinicals Pvt Ltd, Pune, India Rahul Kapse Co-author Bion Clinicals Pvt Ltd, Pune, India Vinod Deshmukh Co-author Bion Clinicals Pvt Ltd, Pune, India Dr Nutan Gangurde Co-author Bion Clinicals Pvt Ltd, Pune, India Swarali bhakare Co-author Bion Clinicals Pvt Ltd, Pune, India Swapnali Salunke Co-author Bion Clinicals Pvt Ltd, Pune, India Ashwini Mokate Co-author Bion Clinicals Pvt Ltd, Pune, India V
At two years, 83% are off of it
Semaglutide is a medication used to treat type 2 diabetes and to support weight loss in people who meet certain health criteria
)
